What is the Marksans Pharma Ltd share price today?

The share price of NSE:MARKSANS-EQ on 01 Oct 2026 (as of 15:04:12 IST) is ₹325.

What is the NSE:MARKSANS-EQ 52 week high low price?

Over the past 52 weeks (as of 01 Oct 2026), the NSE:MARKSANS-EQ 52 week high low range shows a high of ₹350.95 and a low of ₹155.

What is the Marksans Pharma Ltd market cap?

As on 01 Oct 2026, Marksans Pharma Ltd market cap is ₹146032000000.

What is the shareholding pattern of Marksans Pharma Ltd Stock?

The shareholding pattern of Marksans Pharma Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 43.87% Foreign Institutional Investors (FII): 17.47% Domestic Institutional Investors (DII): 1.83% Mutual Funds: 4.36% Retail & Others: 32.47% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Marksans Pharma Ltd?

The Price-to-Earnings (PE) ratio of Marksans Pharma Ltd is 28.2598, and the Price-to-Book (PB) ratio is 2.3582, as on 01 Oct 2026.

Marksans Pharma Share Price

313.60+1.30 (+0.42%)

+72.23% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+0.42%

1 Week

-0.55%

1 Month

-3.69%

3 Month

+15.87%

6 Month

+54.47%

YTD

+73.94%

1 Year

+72.23%

5 Year

+373.00%

10 Year

+524.08%

Max

+14154.55%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

312.00

304.90

282.70

267.25

193.75

155.00

High

317.95

341.95

350.95

About

Marksans Pharma is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

LAURUSLABSNSE

ZYDUSLIFENSE

DRREDDYNSE

CIPLANSE

MANKINDNSE

AUROPHARMANSE

LUPINNSE

MARKSANSNSE

LTP

1W Low

1W High

Market cap (₹)

1769.9+8.9 (0.51%)

1722

1855

4,24,202Cr

10064+400 (4.14%)

9621.50

10064

2,64,141Cr

4650+70 (1.53%)

4532

4675

1,74,402Cr

2323+79 (3.52%)

2206.10

2441.90

1,26,811Cr

1240.6+56.2 (4.75%)

1182

1254.20

1,23,685Cr

1368.3+23.3 (1.73%)

1336.70

1368.30

1,11,868Cr

1396.9+38.9 (2.86%)

1357

1396.90

1,11,650Cr

2475+5.7 (0.23%)

2457.90

2528

1,02,196Cr

1694.5+34.6 (2.08%)

1647.20

1697.40

96,951Cr

2015.9+26 (1.31%)

1974

2033.80

91,301Cr

315.3-0.05 (-0.02%)

304.90

317.95

14,157Cr

Marksans Pharma Share Price

313.60+1.30 (+0.42%)

+72.23% past 1 Year

Financial overview

Compounded Sales Growth

10 years13%

5 years16%

3 years17%

Last year13%

Compounded Profit Growth

10 years18%

5 years12%

3 years16%

Last year10%

Stock Price CAGR

10 years20%

5 years36%

3 years42%

1 year72%

Return on Equity

10 years16%

5 years17%

3 years16%

Last year15%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
13%	16%	17%	13%
18%	12%	16%	10%
20%	36%	42%	72%
16%	17%	16%	15%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

LAURUSLABS

ZYDUSLIFE

DRREDDY

CIPLA

MANKIND

AUROPHARMA

LUPIN

MARKSANS

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,777.1	₹424202 Cr	38.68	8.29	58.23	₹11479 Cr
9,891.5	₹264141 Cr	90.3	34.04	128.41	₹2568 Cr
4,616.5	₹174402 Cr	82.11	14.04	106.21	₹2163 Cr
2,287.8	₹126811 Cr	94.64	8.17	33.94	₹889 Cr
1,237.4	₹123685 Cr	27.41	9.42	62.53	₹5040 Cr
1,355.5	₹111868 Cr	39.95	11.08	59.2	₹4196 Cr
1,385.5	₹111650 Cr	38.54	10.86	52.6	₹3879 Cr
2,475.1	₹102196 Cr	45.57	17.23	76.26	₹1913 Cr
1,681.1	₹96951 Cr	26.11	17.95	96.84	₹3505 Cr
2,007.1	₹91301 Cr	16.51	30.95	154.35	₹5333 Cr
313.6	₹14157 Cr	27.4	3.47	13.62	₹418 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Name

Net Revenue

Other Income

Total Revenue

Total Expenditure

Operating Profit

Interest Expense

PBT

Net Profit

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022	Dec 2021	Sep 2021	Jun 2021	Mar 2021	Dec 2020	Sep 2020	Jun 2020	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Mar 2019	Dec 2018	Sep 2018	Jun 2018	Mar 2018	Dec 2017	Sep 2017	Jun 2017	Mar 2017	Dec 2016	Sep 2016	Jun 2016	Mar 2016	Dec 2015	Sep 2015	Jun 2015	Mar 2015	Dec 2014	Sep 2014	Jun 2014	Mar 2014	Dec 2013	Sep 2013	Jun 2013	Mar 2013	Dec 2012	Sep 2012
₹841 Cr	₹856 Cr	₹754 Cr	₹720 Cr	₹620 Cr	₹708 Cr	₹682 Cr	₹642 Cr	₹591 Cr	₹560 Cr	₹586 Cr	₹531 Cr	₹500 Cr	₹486 Cr	₹480 Cr	₹453 Cr	₹434 Cr	₹418 Cr	₹363 Cr	₹361 Cr	₹349 Cr	₹330 Cr	₹358 Cr	₹356 Cr	₹331 Cr	₹335 Cr	₹288 Cr	₹256 Cr	₹245 Cr	₹247 Cr	₹248 Cr	₹269 Cr	₹235 Cr	₹199 Cr	₹218 Cr	₹274 Cr	₹221 Cr	₹178 Cr	₹215 Cr	₹180 Cr	₹187 Cr	₹217 Cr	₹218 Cr	₹256 Cr	₹212 Cr	₹174 Cr	₹213 Cr	₹211 Cr	₹202 Cr	₹160 Cr	₹169 Cr	₹161 Cr	₹144 Cr	₹124 Cr	₹115 Cr	₹109 Cr
₹25 Cr	₹35 Cr	₹20 Cr	₹22 Cr	₹6 Cr	₹15 Cr	₹36 Cr	-₹7 L	₹15 Cr	₹17 Cr	₹5 Cr	₹19 Cr	₹10 Cr	₹11 Cr	₹18 Cr	₹14 Cr	₹16 Cr	₹15 Cr	₹12 Cr	₹9 Cr	₹6 Cr	₹6 Cr	-₹3 Cr	₹4 Cr	₹18 L	₹3 L	₹3 L	₹8 Cr	₹2 Cr	₹10 Cr	₹16 L	-₹80 L	₹3 Cr	₹0	₹39 L	₹0	₹4 L	₹7 Cr	₹0	₹7 Cr	₹1 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹866 Cr	₹891 Cr	₹775 Cr	₹742 Cr	₹626 Cr	₹724 Cr	₹718 Cr	₹642 Cr	₹606 Cr	₹577 Cr	₹591 Cr	₹550 Cr	₹510 Cr	₹497 Cr	₹497 Cr	₹467 Cr	₹450 Cr	₹433 Cr	₹375 Cr	₹370 Cr	₹355 Cr	₹336 Cr	₹355 Cr	₹360 Cr	₹331 Cr	₹335 Cr	₹288 Cr	₹264 Cr	₹247 Cr	₹257 Cr	₹249 Cr	₹268 Cr	₹238 Cr	₹199 Cr	₹219 Cr	₹274 Cr	₹221 Cr	₹185 Cr	₹215 Cr	₹187 Cr	₹187 Cr	₹217 Cr	₹218 Cr	₹256 Cr	₹212 Cr	₹174 Cr	₹213 Cr	₹211 Cr	₹202 Cr	₹160 Cr	₹169 Cr	₹161 Cr	₹144 Cr	₹124 Cr	₹115 Cr	₹109 Cr
₹653 Cr	₹685 Cr	₹618 Cr	₹603 Cr	₹543 Cr	₹604 Cr	₹572 Cr	₹515 Cr	₹483 Cr	₹471 Cr	₹475 Cr	₹435 Cr	₹412 Cr	₹390 Cr	₹416 Cr	₹386 Cr	₹372 Cr	₹376 Cr	₹313 Cr	₹308 Cr	₹279 Cr	₹236 Cr	₹276 Cr	₹292 Cr	₹268 Cr	₹276 Cr	₹248 Cr	₹228 Cr	₹217 Cr	₹238 Cr	₹217 Cr	₹237 Cr	₹206 Cr	₹202 Cr	₹196 Cr	₹256 Cr	₹200 Cr	₹185 Cr	₹200 Cr	₹186 Cr	₹178 Cr	₹214 Cr	₹197 Cr	₹210 Cr	₹165 Cr	₹136 Cr	₹165 Cr	₹164 Cr	₹164 Cr	₹139 Cr	₹139 Cr	₹135 Cr	₹121 Cr	₹83 Cr	₹102 Cr	₹91 Cr
₹238 Cr	₹231 Cr	₹181 Cr	₹166 Cr	₹106 Cr	₹142 Cr	₹167 Cr	₹147 Cr	₹143 Cr	₹126 Cr	₹138 Cr	₹133 Cr	₹112 Cr	₹121 Cr	₹94 Cr	₹94 Cr	₹89 Cr	₹79 Cr	₹70 Cr	₹69 Cr	₹83 Cr	₹101 Cr	₹88 Cr	₹87 Cr	₹70 Cr	₹69 Cr	₹47 Cr	₹41 Cr	₹35 Cr	₹25 Cr	₹36 Cr	₹36 Cr	₹39 Cr	₹4 Cr	₹29 Cr	₹25 Cr	₹29 Cr	₹8 Cr	₹27 Cr	₹7 Cr	₹13 Cr	₹11 Cr	₹31 Cr	₹51 Cr	₹52 Cr	₹42 Cr	₹52 Cr	₹51 Cr	₹43 Cr	₹24 Cr	₹36 Cr	₹30 Cr	₹26 Cr	₹42 Cr	₹19 Cr	₹23 Cr
₹7 Cr	₹6 Cr	₹6 Cr	₹6 Cr	₹6 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹3 Cr	₹5 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹5 Cr	₹95 L	₹2 Cr	₹97 L	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹2 Cr	₹2 Cr	₹3 Cr	₹3 Cr	₹1 Cr	₹6 Cr	₹5 Cr	₹4 Cr	₹4 Cr	₹3 Cr	₹4 Cr	₹3 Cr	₹4 Cr	₹4 Cr	₹3 Cr
₹207 Cr	₹200 Cr	₹151 Cr	₹133 Cr	₹77 Cr	₹116 Cr	₹143 Cr	₹125 Cr	₹120 Cr	₹100 Cr	₹113 Cr	₹114 Cr	₹97 Cr	₹104 Cr	₹79 Cr	₹78 Cr	₹76 Cr	₹53 Cr	₹60 Cr	₹60 Cr	₹75 Cr	₹97 Cr	₹78 Cr	₹66 Cr	₹61 Cr	₹58 Cr	₹38 Cr	₹34 Cr	₹28 Cr	₹17 Cr	₹30 Cr	₹28 Cr	₹30 Cr	-₹6 Cr	₹21 Cr	₹15 Cr	₹20 Cr	-₹1 Cr	₹13 Cr	-₹8 L	₹7 Cr	₹43 L	₹18 Cr	₹43 Cr	₹45 Cr	₹36 Cr	₹42 Cr	₹42 Cr	₹35 Cr	₹17 Cr	₹27 Cr	₹22 Cr	₹20 Cr	₹37 Cr	₹9 Cr	₹15 Cr
₹159 Cr	₹149 Cr	₹114 Cr	₹99 Cr	₹58 Cr	₹91 Cr	₹105 Cr	₹98 Cr	₹89 Cr	₹78 Cr	₹83 Cr	₹84 Cr	₹70 Cr	₹83 Cr	₹62 Cr	₹60 Cr	₹60 Cr	₹30 Cr	₹48 Cr	₹46 Cr	₹63 Cr	₹79 Cr	₹59 Cr	₹51 Cr	₹49 Cr	₹43 Cr	₹30 Cr	₹26 Cr	₹22 Cr	₹10 Cr	₹25 Cr	₹21 Cr	₹25 Cr	-₹6 Cr	₹17 Cr	₹10 Cr	₹14 Cr	-₹3 Cr	₹12 Cr	₹75 L	₹5 Cr	-₹4 Cr	₹19 Cr	₹36 Cr	₹32 Cr	₹26 Cr	₹28 Cr	₹32 Cr	₹26 Cr	₹11 Cr	₹23 Cr	₹21 Cr	₹19 Cr	₹42 Cr	₹9 Cr	₹15 Cr

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Unsecured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Miscellaneous Expenses not written off

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010	Mar 2009	Mar 2008
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹45 Cr	₹45 Cr	₹45 Cr	₹45 Cr	₹41 Cr	₹41 Cr	₹41 Cr	₹41 Cr	₹41 Cr	₹41 Cr	₹53 Cr	₹53 Cr	₹52 Cr	₹52 Cr	₹50 Cr	₹50 Cr	₹50 Cr	₹50 Cr	₹49 Cr
₹3 Cr	₹0	₹0	₹0	₹93 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹1 Cr	₹3 Cr	₹0	₹0	₹0
₹2975 Cr	₹2422 Cr	₹2020 Cr	₹1700 Cr	₹1068 Cr	₹846 Cr	₹595 Cr	₹502 Cr	₹430 Cr	₹393 Cr	₹401 Cr	₹326 Cr	₹90 Cr	₹34 Cr	-₹220 Cr	-₹115 Cr	₹111 Cr	₹100 Cr	₹92 Cr
₹2975 Cr	₹2422 Cr	₹2020 Cr	₹1700 Cr	₹1068 Cr	₹846 Cr	₹595 Cr	₹502 Cr	₹430 Cr	₹393 Cr	₹401 Cr	₹326 Cr	₹90 Cr	₹34 Cr	-₹220 Cr	-₹115 Cr	₹111 Cr	₹100 Cr	₹92 Cr
₹3023 Cr	₹2467 Cr	₹2065 Cr	₹1745 Cr	₹1202 Cr	₹886 Cr	₹636 Cr	₹542 Cr	₹471 Cr	₹433 Cr	₹454 Cr	₹380 Cr	₹142 Cr	₹86 Cr	-₹168 Cr	-₹63 Cr	₹161 Cr	₹150 Cr	₹142 Cr
₹30 Cr	₹22 Cr	₹21 Cr	₹20 Cr	₹21 Cr	₹19 Cr	₹13 Cr	₹10 Cr	₹10 Cr	₹6 Cr	₹8 Cr	₹8 Cr	₹7 Cr	₹7 Cr	₹6 Cr	₹0	₹91 L	₹69 L	₹27 L
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹20 Cr	₹8 Cr	₹15 Cr	₹19 Cr	₹247 Cr	₹195 Cr	₹138 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹177 Cr	₹201 Cr	₹200 Cr
-₹8 Cr	₹4 Cr	₹11 Cr	₹15 Cr	₹14 Cr	₹7 Cr	₹10 Cr	₹6 Cr	₹5 Cr	₹4 Cr	-₹2 Cr	₹1 Cr	₹2 Cr	₹3 Cr	₹13 Cr	₹16 Cr	₹12 Cr	₹12 Cr	₹11 Cr
₹270 Cr	₹263 Cr	₹190 Cr	₹66 Cr	₹41 Cr	₹14 Cr	₹13 Cr	₹10 Cr	₹10 Cr	₹11 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹6 Cr	₹6 Cr	₹5 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹1 Cr	₹96 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹268 Cr	₹273 Cr	₹205 Cr	₹84 Cr	₹57 Cr	₹24 Cr	₹24 Cr	₹17 Cr	₹16 Cr	₹16 Cr	-₹2 Cr	₹1 Cr	₹22 Cr	₹10 Cr	₹28 Cr	₹35 Cr	₹436 Cr	₹408 Cr	₹349 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹337 Cr	₹306 Cr	₹268 Cr	₹231 Cr	₹200 Cr	₹169 Cr	₹110 Cr	₹106 Cr	₹78 Cr	₹162 Cr	₹119 Cr	₹107 Cr	₹83 Cr	₹56 Cr	₹59 Cr	₹55 Cr	₹59 Cr	₹81 Cr	₹69 Cr
₹119 Cr	₹117 Cr	₹71 Cr	₹42 Cr	₹97 Cr	₹80 Cr	₹59 Cr	₹21 Cr	₹10 Cr	₹71 L	₹68 L	₹40 Cr	₹97 Cr	₹109 Cr	₹336 Cr	₹342 Cr	₹0	₹1 L	₹1 L
₹30 Cr	₹23 Cr	₹29 Cr	₹42 Cr	₹41 Cr	₹19 Cr	₹19 Cr	₹100 Cr	₹117 Cr	₹110 Cr	₹88 Cr	₹82 Cr	₹106 Cr	₹114 Cr	₹114 Cr	₹116 Cr	₹0	₹0	₹0
₹42 Cr	₹31 Cr	₹22 Cr	₹27 Cr	₹42 Cr	₹32 Cr	₹41 Cr	₹6 Cr	₹29 Cr	₹24 Cr	₹52 Cr	₹57 Cr	₹34 Cr	₹19 Cr	₹10 Cr	₹7 Cr	₹9 L	₹1 Cr	₹3 Cr
₹527 Cr	₹477 Cr	₹390 Cr	₹341 Cr	₹380 Cr	₹299 Cr	₹229 Cr	₹233 Cr	₹235 Cr	₹296 Cr	₹259 Cr	₹286 Cr	₹319 Cr	₹297 Cr	₹519 Cr	₹520 Cr	₹60 Cr	₹82 Cr	₹71 Cr
₹3848 Cr	₹3240 Cr	₹2681 Cr	₹2190 Cr	₹1660 Cr	₹1228 Cr	₹902 Cr	₹802 Cr	₹731 Cr	₹752 Cr	₹720 Cr	₹676 Cr	₹490 Cr	₹401 Cr	₹385 Cr	₹492 Cr	₹658 Cr	₹642 Cr	₹562 Cr
₹0	₹0	₹0	₹1 Cr	₹1 Cr	₹20 Cr	₹48 Cr	₹30 Cr	₹11 Cr	₹9 Cr	₹10 Cr	₹17 Cr	₹84 Cr	₹237 Cr	₹152 Cr	₹16 Cr	₹2 Cr	₹3 Cr	₹4 Cr
₹30 Cr	₹23 Cr	₹29 Cr	₹42 Cr	₹41 Cr	₹19 Cr	₹19 Cr	₹100 Cr	₹118 Cr	₹110 Cr	₹88 Cr	₹89 Cr	₹160 Cr	₹163 Cr	₹179 Cr	₹187 Cr	₹424 Cr	₹397 Cr	₹338 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹1605 Cr	₹1413 Cr	₹1135 Cr	₹828 Cr	₹726 Cr	₹552 Cr	₹565 Cr	₹506 Cr	₹495 Cr	₹456 Cr	₹429 Cr	₹298 Cr	₹262 Cr	₹257 Cr	₹251 Cr	₹340 Cr	₹485 Cr	₹459 Cr	₹334 Cr
₹561 Cr	₹431 Cr	₹359 Cr	₹342 Cr	₹298 Cr	₹243 Cr	₹263 Cr	₹237 Cr	₹216 Cr	₹190 Cr	₹160 Cr	₹132 Cr	₹116 Cr	₹101 Cr	₹85 Cr	₹62 Cr	₹94 Cr	₹79 Cr	₹64 Cr
₹1044 Cr	₹982 Cr	₹776 Cr	₹486 Cr	₹428 Cr	₹309 Cr	₹303 Cr	₹270 Cr	₹279 Cr	₹267 Cr	₹270 Cr	₹166 Cr	₹146 Cr	₹156 Cr	₹165 Cr	₹279 Cr	₹392 Cr	₹380 Cr	₹270 Cr
₹15 Cr	₹9 Cr	₹5 Cr	₹7 Cr	₹70 L	₹6 Cr	₹0	₹0	₹0	₹36 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹10 Cr	₹0	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹10 Cr	₹0	₹0
₹22 Cr	₹26 Cr	₹33 Cr	₹19 Cr	₹4 Cr	₹4 Cr	₹6 Cr	₹1 Cr	₹82 L	₹59 L	₹10 Cr	₹83 L	₹2 Cr	₹1 Cr	₹4 Cr	₹4 Cr	₹0	₹0	₹0
₹1 L	₹17 L	₹17 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹1125 Cr	₹1036 Cr	₹818 Cr	₹515 Cr	₹435 Cr	₹325 Cr	₹308 Cr	₹271 Cr	₹280 Cr	₹268 Cr	₹280 Cr	₹167 Cr	₹147 Cr	₹157 Cr	₹169 Cr	₹282 Cr	₹402 Cr	₹380 Cr	₹270 Cr
—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
₹0	₹74 L	₹27 Cr	₹54 L	₹44 L	₹26 L	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹972 Cr	₹846 Cr	₹618 Cr	₹485 Cr	₹424 Cr	₹404 Cr	₹242 Cr	₹293 Cr	₹218 Cr	₹190 Cr	₹168 Cr	₹130 Cr	₹103 Cr	₹78 Cr	₹73 Cr	₹67 Cr	₹105 Cr	₹119 Cr	₹139 Cr
₹645 Cr	₹540 Cr	₹453 Cr	₹417 Cr	₹395 Cr	₹272 Cr	₹243 Cr	₹177 Cr	₹177 Cr	₹248 Cr	₹217 Cr	₹183 Cr	₹170 Cr	₹131 Cr	₹113 Cr	₹99 Cr	₹95 Cr	₹102 Cr	₹65 Cr
₹990 Cr	₹704 Cr	₹674 Cr	₹715 Cr	₹349 Cr	₹212 Cr	₹94 Cr	₹34 Cr	₹40 Cr	₹25 Cr	₹35 Cr	₹185 Cr	₹47 Cr	₹16 Cr	₹22 Cr	₹31 Cr	₹36 Cr	₹22 Cr	₹62 Cr
₹40 Cr	₹32 Cr	₹31 Cr	₹23 Cr	₹24 Cr	₹13 Cr	₹11 Cr	₹28 Cr	₹16 Cr	₹9 L	₹0	₹0	₹0	₹0	₹0	₹1 L	₹0	₹0	₹0
₹76 Cr	₹81 Cr	₹60 Cr	₹35 Cr	₹32 Cr	₹98 L	₹3 Cr	₹0	₹0	₹21 Cr	₹20 Cr	₹10 Cr	₹24 Cr	₹19 Cr	₹7 Cr	₹12 Cr	₹21 Cr	₹18 Cr	₹25 Cr
₹2723 Cr	₹2204 Cr	₹1862 Cr	₹1675 Cr	₹1225 Cr	₹903 Cr	₹594 Cr	₹531 Cr	₹451 Cr	₹484 Cr	₹440 Cr	₹509 Cr	₹343 Cr	₹244 Cr	₹216 Cr	₹209 Cr	₹256 Cr	₹261 Cr	₹291 Cr
₹2196 Cr	₹1727 Cr	₹1473 Cr	₹1334 Cr	₹845 Cr	₹604 Cr	₹365 Cr	₹299 Cr	₹216 Cr	₹188 Cr	₹181 Cr	₹223 Cr	₹24 Cr	-₹53 Cr	-₹304 Cr	-₹310 Cr	₹196 Cr	₹179 Cr	₹219 Cr
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹21 L	₹48 L	₹1 Cr
₹3848 Cr	₹3240 Cr	₹2681 Cr	₹2190 Cr	₹1660 Cr	₹1228 Cr	₹902 Cr	₹802 Cr	₹731 Cr	₹752 Cr	₹720 Cr	₹676 Cr	₹490 Cr	₹401 Cr	₹385 Cr	₹492 Cr	₹658 Cr	₹642 Cr	₹562 Cr
₹67	₹54	₹46	₹39	₹27	₹22	₹16	₹13	₹12	₹11	₹11	₹9	₹3	₹2	-₹5	-₹2	₹4	₹4	₹4
₹67	₹54	₹46	₹39	₹27	₹22	₹16	₹13	₹12	₹11	₹11	₹9	₹3	₹2	-₹5	-₹2	₹4	₹4	₹4

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Effect of Foreign Exchange Fluctuations

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	Mar 2013	Mar 2012	Mar 2011	Mar 2010	Mar 2009	Mar 2008
₹561 Cr	₹504 Cr	₹424 Cr	₹338 Cr	₹248 Cr	₹302 Cr	₹157 Cr	₹104 Cr	₹50 Cr	₹15 Cr	₹107 Cr	₹156 Cr	₹72 Cr	₹46 Cr	-₹179 Cr	-₹223 Cr	-₹10 Cr	-₹8 Cr	₹15 Cr
₹100 Cr	₹69 Cr	₹55 Cr	₹74 Cr	₹35 Cr	₹57 Cr	₹42 Cr	₹32 Cr	₹44 Cr	₹27 Cr	₹40 Cr	₹24 Cr	₹20 Cr	₹28 Cr	₹124 Cr	₹113 Cr	₹31 Cr	₹22 Cr	₹10 Cr
-₹62 Cr	-₹241 Cr	-₹126 Cr	-₹111 Cr	-₹111 Cr	-₹132 Cr	₹59 Cr	-₹82 Cr	-₹36 Cr	-₹6 Cr	-₹88 Cr	₹19 Cr	-₹27 Cr	-₹35 Cr	-₹8 Cr	₹46 Cr	-₹4 Cr	₹6 Cr	-₹2 Cr
₹598 Cr	₹333 Cr	₹353 Cr	₹300 Cr	₹172 Cr	₹227 Cr	₹258 Cr	₹54 Cr	₹58 Cr	₹35 Cr	₹58 Cr	₹199 Cr	₹65 Cr	₹39 Cr	-₹62 Cr	-₹65 Cr	₹17 Cr	₹20 Cr	₹23 Cr
₹458 Cr	₹207 Cr	₹230 Cr	₹237 Cr	₹99 Cr	₹179 Cr	₹233 Cr	₹27 Cr	₹50 Cr	₹14 Cr	₹31 Cr	₹155 Cr	₹65 Cr	₹39 Cr	-₹62 Cr	-₹65 Cr	₹17 Cr	₹20 Cr	₹23 Cr
-₹248 Cr	-₹49 Cr	-₹141 Cr	-₹259 Cr	-₹84 Cr	-₹45 Cr	-₹60 Cr	-₹13 Cr	-₹39 Cr	-₹21 Cr	-₹123 Cr	-₹33 Cr	-₹4 Cr	-₹5 Cr	-₹3 Cr	₹25 Cr	-₹35 Cr	-₹118 Cr	-₹134 Cr
-₹71 Cr	-₹65 Cr	-₹69 Cr	₹198 Cr	₹80 Cr	-₹15 Cr	-₹114 Cr	-₹21 Cr	₹3 Cr	-₹3 Cr	-₹58 Cr	₹17 Cr	-₹29 Cr	-₹40 Cr	₹57 Cr	₹36 Cr	₹32 Cr	₹59 Cr	₹14 Cr
₹139 Cr	₹93 Cr	₹21 Cr	₹176 Cr	₹94 Cr	₹118 Cr	₹60 Cr	-₹7 Cr	₹15 Cr	-₹10 Cr	-₹150 Cr	₹138 Cr	₹31 Cr	-₹7 Cr	-₹9 Cr	-₹5 Cr	₹13 Cr	-₹39 Cr	-₹97 Cr
₹496 Cr	₹403 Cr	₹382 Cr	₹206 Cr	₹112 Cr	₹94 Cr	₹34 Cr	₹40 Cr	₹25 Cr	₹35 Cr	₹185 Cr	₹47 Cr	₹16 Cr	₹22 Cr	₹31 Cr	₹36 Cr	₹22 Cr	₹62 Cr	₹159 Cr
-₹58 L	₹0	₹0	₹20,000	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹634 Cr	₹496 Cr	₹403 Cr	₹382 Cr	₹206 Cr	₹212 Cr	₹94 Cr	₹33 Cr	₹40 Cr	₹25 Cr	₹35 Cr	₹185 Cr	₹47 Cr	₹16 Cr	₹22 Cr	₹31 Cr	₹36 Cr	₹22 Cr	₹62 Cr

Fundamental Ratios

Consolidated

Standalone

No results found

Marksans Pharma Share Price

313.60+1.30 (+0.42%)

+72.23% past 1 Year

Technical meters

Oscillators

Strong SellSellNeutralBuyStrong Buy

Bullish signals: 1

Bearish signals: 6 out of 9 oscillators

RSI

51.43Neutral

STOCH %K

80.89Sell

MACD Level(12,26)

-3.19Sell

Ultimate Oscillator

55.18Buy

Aroon Oscillator

-38.00Sell

BOP

-0.32Sell

CCI

50.83Neutral

Williams %R

-19.11Sell

Momentum

-3.65Sell

Moving averages

Strong SellSellNeutralBuyStrong Buy

Bullish signals: 8

Bearish signals: 1 out of 9 moving averages

EMA 9

307.92Buy

SMA 9

303.42Buy

EMA 21

310.16Buy

SMA 21

309.38Buy

EMA 50

309.51Buy

SMA 50

320.57Sell

EMA 200

263.75Buy

SMA 200

241.23Buy

WMA 20

306.05Buy

Pivot

Classic

Resistance 5

345.30

Resistance 4

336.70

Resistance 3

328.10

Resistance 2

319.50

Resistance 1

315.90

Pivot

310.90

Support 1

307.30

Support 2

302.30

Support 3

293.70

Support 4

285.10

Support 5

276.50

High & lows

1 Day

1 Week

1 Month

3 Months

6 Months

Year to Date

1 Year

3 Years

5 Years

10 Years

All Time

Low

312.00

304.90

282.70

267.25

193.75

155.00

109.20

38.60

9.85

0.87

High

317.95

341.95

350.95

358.70

Returns

+1.30

-1.75

-12.00

+42.95

+110.58

+133.31

+131.52

+204.40

+247.30

+263.35

+311.40

Beta

—

Std. deviation %

—

Open a free Demat account in minutes to start investing and screening .

Marksans Pharma Share Price

313.60+1.30 (+0.42%)

+72.23% past 1 Year

Shareholding summary

Promoters

43.87%

FII

19.06%

DII

1.82%

3.72%

Others

31.53%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Sep 2026	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025
43.87%	43.87%	43.87%	43.87%	43.87%	43.87%
19.06%	17.47%	16.76%	8.13%	16.92%	19.89%
1.82%	1.83%	1.91%	1.50%	1.36%	1.95%
3.72%	4.36%	4.66%	4.41%	3.92%	3.55%
31.53%	32.47%	32.80%	42.09%	33.93%	30.74%

Bulk & block deals

Name

Microcurves Trading Private Limited

Unifi Capital Private Limited

Unifi Blend Fund 2

Orbimed Asia Iv Mauritius Fvci Limited

Unifi Capital Private Limited -Blended Rangoli

Uti Mutual Fund

Unifi Capital Private Limited

Unifi Bcad Fund

Societe Generale

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
12 Aug 2026	Sell	136.32 Cr	₹313.40	43.50 L	Bulk	0.959851	NSE
12 Aug 2026	Purchase	136.25 Cr	₹313.24	43.50 L	Bulk	0.959851	NSE
28 Jul 2025	Purchase	167.64 Cr	₹231.50	72.41 L	Bulk	1.597946	BSE
11 Jun 2025	Purchase	74.98 Cr	₹249.95	30 L	Bulk	0.662012	NSE
11 Jun 2025	Sell	256.78 Cr	₹249.95	1.03 Cr	Bulk	2.267049	NSE
11 Jun 2025	Purchase	81.17 Cr	₹249.95	32.48 L	Block	0.716651	NSE
11 Jun 2025	Purchase	10.35 Cr	₹249.95	4.14 L	Block	0.091378	NSE
11 Jun 2025	Purchase	14.85 Cr	₹249.95	5.94 L	Block	0.131078	NSE
11 Jun 2025	Purchase	14 Cr	₹249.95	5.60 L	Block	0.123576	NSE
11 Jun 2025	Purchase	23 Cr	₹249.95	9.20 L	Block	0.203058	NSE

Insider trading & SAST

Client name

Merrill Jean Saldanha

Marise Ann Saldanha

Sandra Saldanha

Schenelle Megan Saldanha

Orbimed Asia Iv Mauritius Fvci Ltd

Sandra Saldanha

Arvind Singh

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
17 Sep 2026	Directors Immediate Relative	Acquisition	0.013963	0.01	0	—	63.27 K	11 Sep 2026	Gift	63,273	Insider Trading	—	Equity
17 Sep 2026	Directors Immediate Relative	Acquisition	0.004413	0	0	—	20 K	11 Sep 2026	Gift	20,000	Insider Trading	—	Equity
17 Sep 2026	Director	Disposal	0.050373	0.02	0	—	2.28 L	11 Sep 2026	Gift	1,02,183	Insider Trading	—	Equity
17 Sep 2026	Directors Immediate Relative	Acquisition	0.031997	0.03	0	—	1.45 L	11 Sep 2026	Gift	1,45,000	Insider Trading	—	Equity
09 Jul 2025	Other	Disposal	2.27	8.62	0	—	1.03 Cr	11 Jun 2025	Market	3,90,50,881	SAST	29(2)	—
06 Jun 2024	Promoter	Acquisition	0.013963	0.07	89.52 L	₹141.48	63.28 K	05 Jun 2024	Market Purchase	3,30,456	Insider Trading	—	Equity Shares
04 Jun 2024	Promoter	Acquisition	0.010372	0.06	68.62 L	₹146.01	47 K	03 Jun 2024	Market Purchase	2,67,180	Insider Trading	—	Equity Shares
22 Aug 2023	Employee	Acquisition	0.000662	0	3.47 L	₹115.75	3 K	14 Aug 2023 - 18 Aug 2023	Market Purchase	3,000	Insider Trading	—	Equity Shares
22 Aug 2023	Employee	Disposal	0.001434	0	7.61 L	₹117.06	6.50 K	14 Aug 2023 - 18 Aug 2023	Market Sale	5,000	Insider Trading	—	Equity Shares
22 Aug 2023	Employee	Disposal	0.000441	0	3.28 L	₹163.92	2 K	14 Aug 2023 - 18 Aug 2023	Market Sale	3,000	Insider Trading	—	Equity Shares

Marksans Pharma Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Marksans Pharma Share Price

Marksans Pharma Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Marksans Pharma Share Price

Marksans Pharma Share Price

Oscillators

Moving averages

Marksans Pharma Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Marksans Pharma Share Price

Corporate Actions

Company details

Marksans Pharma Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Marksans Pharma Share Price

News

Marksans Pharma to host analyst and investor meeting on September 2nd

Marksans Pharma reports strong quarterly EBITDA growth and margin expansion

Marksans Pharma posts strong Q1 revenue growth to Rs 841 crores

Marksans Pharma posts sharp rise in quarterly net profit

Marksans Pharma to host Q1 FY27 earnings conference call on August 13

Marksans Pharma fully acquires Germany-based pharma distributor ABCnow GmbH

Marksans Pharma informs about press release

Marksans Pharma inks definitive pact to acquire 100% stake in QliniQ B.V.

Marksans Pharma to acquire Qliniq B.V. to expand European market presence

Marksans Pharma targets Rs 4,000 crores revenue by FY28 with margin guidance

Marksans Pharma outlines US launches and new geography revenue timelines

Marksans Pharma outlines Australia growth and M&A timeline towards FY27-28

Marksans Pharma - Quaterly Results

Marksans Pharma posts record revenue and EBITDA, beats margin guidance

Marksans Pharma plans to expand North America presence through US store brands

Marksans Pharma reports Profit after tax of 91.92 Crores, in the March 2026 quarter

Marksans Pharma Q4 EBITDA surges with strong margin expansion year-on-year

Marksans Pharma reports strong year-on-year Q4 revenue growth on higher sales base

Marksans Pharma Q4 consolidated net profit surges sharply year-on-year

Marksans Pharma informs about press release

Marksans Pharma Ltd Share Price Today

Marksans Pharma Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator